RGRX
REGENERX BIOPHARMS INC
stockOTC
regenerx is a publicly traded, clinical-stage, biopharmaceutical company focused on tissue protection, repair and regeneration. regenerx's mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. regenerx's management team is focused on moving three distinct tβ4-based drug candidates through the clinic: rgn-137, rgn-259 and rgn-352. regenerx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. currently, regenerx has active partnerships in three major territories: the u.s. and canada, china, and pan asia. our partners have been moving forward and making significant progress in each territory with rgn-259, our ophthalmic drug candidate, and are preparing to initiate their clinical trials programs. in each case, the cost of development is being borne by our partners with no financial ob
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 3M | 0.00 | 2026-06-30 | +83.33% | 9.424 |
| 6M | 0.00 | 2026-04-13 | +120.00% | 8.817 |
| 1Y | 0.16 | 2025-10-09 | -99.32% | 1819.644 |
| 2Y | 0.00 | 2024-10-11 | -21.43% | — |
| 5Y | 18.45 | 2021-10-08 | -99.99% | 61.501 |
REGENERX BIOPHARMS INC (OTC:RGRX) stock price today is $0.00, and today's volume is 1,292. RGRX is up 0.000% today. The 30 day average volume is 1,564. RGRX market cap is $165,945 with 150.86M shares outstanding.